Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Ferumoxytol Injection [Feraheme]

Phase 3

SStanford University

Ferumoxytol Injection [Feraheme] is one of 2 therapeutic programs targeting Pregnancy Related. It is currently in Phase 3.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[2][1]

Indication

Pregnancy RelatedCompleted

Pregnancy RelatedPhase 3

Completed

Competition

Competitive Landscape

1 competitor in Pregnancy Related

#DrugCompanyPhaseTrials

Feosol

AAuerbach Hematology Oncology Associates P C

Ferumoxytol Injection [Feraheme]

SStanford University

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pregnancy Related1 trial

Comparison of Oral Ferrous Sulfate to Intravenous Ferumoxytol in Antepartum Iron Deficiency Anemia

Completed·SStanford University·Phase 3·NCT04253626·83 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ferumoxytol Injection [Feraheme]. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ferumoxytol Injection [Feraheme]. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: SStanford University

Related News